152 related articles for article (PubMed ID: 33863290)
1. Cancer immune control dynamics: a clinical data driven model of systemic immunity in patients with metastatic melanoma.
Frisch HP; Sprau A; McElroy VF; Turner JD; Becher LRE; Nevala WK; Leontovich AA; Markovic SN
BMC Bioinformatics; 2021 Apr; 22(1):197. PubMed ID: 33863290
[TBL] [Abstract][Full Text] [Related]
2. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
3. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment.
Marzagalli M; Ebelt ND; Manuel ER
Semin Cancer Biol; 2019 Dec; 59():236-250. PubMed ID: 31404607
[TBL] [Abstract][Full Text] [Related]
4. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM
J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cell monitoring in cutaneous melanoma - new dynamic biomarker.
Isvoranu G; Surcel M; Huică RI; Munteanu AN; Pîrvu IR; Ciotaru D; Constantin C; Bratu O; Neagu M; Ursaciuc C
Oncol Lett; 2019 May; 17(5):4197-4206. PubMed ID: 30944615
[TBL] [Abstract][Full Text] [Related]
6. Costimulatory Molecules and Immune Checkpoints Are Differentially Expressed on Different Subsets of Dendritic Cells.
Carenza C; Calcaterra F; Oriolo F; Di Vito C; Ubezio M; Della Porta MG; Mavilio D; Della Bella S
Front Immunol; 2019; 10():1325. PubMed ID: 31244860
[TBL] [Abstract][Full Text] [Related]
7. T-cell-directed cancer vaccines: the melanoma model.
Wang E; Phan GQ; Marincola FM
Expert Opin Biol Ther; 2001 Mar; 1(2):277-90. PubMed ID: 11727535
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
9. Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care.
Singh S; Numan A; Agrawal N; Tambuwala MM; Singh V; Kesharwani P
Int Immunopharmacol; 2020 Jun; 83():106417. PubMed ID: 32200155
[TBL] [Abstract][Full Text] [Related]
10. Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile.
Krijgsman D; de Vries NL; Skovbo A; Andersen MN; Swets M; Bastiaannet E; Vahrmeijer AL; van de Velde CJH; Heemskerk MHM; Hokland M; Kuppen PJK
Cancer Immunol Immunother; 2019 Jun; 68(6):1011-1024. PubMed ID: 31053876
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients.
Pirozyan MR; McGuire HM; Emran AA; Tseng HY; Tiffen JC; Lee JH; Carlino MS; Menzies AM; Long GV; Scolyer RA; Fazekas de St Groth B; Hersey P
Front Immunol; 2020; 11():372. PubMed ID: 32210968
[TBL] [Abstract][Full Text] [Related]
12. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
13. Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
Leontovich AA; Dronca RS; Nevala WK; Thompson MA; Kottschade LA; Ivanov LV; Markovic SN;
Melanoma Res; 2017 Feb; 27(1):32-42. PubMed ID: 27824739
[TBL] [Abstract][Full Text] [Related]
14. Intracellular cytokine profile of cord blood T-, and NK- cells and monocytes.
Krampera M; Tavecchia L; Benedetti F; Nadali G; Pizzolo G
Haematologica; 2000 Jul; 85(7):675-9. PubMed ID: 10897117
[TBL] [Abstract][Full Text] [Related]
15. Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.
Kasanen H; Hernberg M; Mäkelä S; Brück O; Juteau S; Kohtamäki L; Ilander M; Mustjoki S; Kreutzman A
Cancer Immunol Immunother; 2020 May; 69(5):717-730. PubMed ID: 32036449
[TBL] [Abstract][Full Text] [Related]
16. Natural-Killer-Derived Extracellular Vesicles: Immune Sensors and Interactors.
Federici C; Shahaj E; Cecchetti S; Camerini S; Casella M; Iessi E; Camisaschi C; Paolino G; Calvieri S; Ferro S; Cova A; Squarcina P; Bertuccini L; Iosi F; Huber V; Lugini L
Front Immunol; 2020; 11():262. PubMed ID: 32231660
[TBL] [Abstract][Full Text] [Related]
17. Mathematical Modeling of Proliferative Immune Response Initiated by Interactions Between Classical Antigen-Presenting Cells Under Joint Antagonistic IL-2 and IL-4 Signaling.
Atitey K; Anchang B
Front Mol Biosci; 2022; 9():777390. PubMed ID: 35155574
[TBL] [Abstract][Full Text] [Related]
18. Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer.
Holl EK; Frazier VN; Landa K; Beasley GM; Hwang ES; Nair SK
Front Immunol; 2019; 10():1767. PubMed ID: 31417550
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
